Ir para o conteúdo principal

ABVC Biopharma (NASDAQ: ABVC) — Perfil da empresa, notícias e dados financeiros

Logo de ABVC Biopharma
ABVC ABVC Biopharma
ABVC Biopharma primary media
Perfil da empresa

ABVC Biopharma

ABVC Biopharma (NASDAQ:ABVC) is a biopharmaceutical company focused on developing and commercializing a diverse range of therapeutic and diagnostic products. It aims to address unmet medical needs in areas such as oncology, central nervous system disorders, and ophthalmology through its innovative research and development strategies. The company's projects range from early-stage discovery to advanced clinical trials, with a commitment to bringing novel treatments and solutions to patients worldwide. ABVC Biopharma pursues partnerships and collaborations to accelerate its product development pipeline and expand its market reach, with the goal of improving patient outcomes and delivering shareholder value.

Resumo

Public USParticipação acionária
2015Ano de fundação
18Funcionários
California, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de ABVC Biopharma

  • Development of the AD101, aimed at treating Alzheimer's Disease, focusing on cognitive enhancement.
  • Biological drug ABV-1501 for treating Major Depressive Disorder, enhancing mood without traditional antidepressant side effects.
  • ABV-1703 targets Pancreatic Cancer, offering potential new therapeutic approach.
  • Innovative drug ABV-1504 for Asthma and Chronic Obstructive Pulmonary Disease (COPD), aimed at improving respiratory function.
  • ABV-1601, designed to address Chronic Kidney Disease, focusing on renal function improvement.
  • Technology platform for Personalized Cancer Medicine, facilitating individualized treatment plans.

equipe executiva do ABVC Biopharma

  • Eugene JiangChairman & Chief Business Officer
  • Uttam Yashwant PatilCEO & Interim CFO
  • Tsung-Shann JiangChief Scientific Officer, Chief Strategy Officer & Director

Principais indicadores financeiros

Resultados divulgados pela ABVC Biopharma, em USD.

Cap. de mercado
29,3 mi
Receita (TTM)
797,9 mil
P/L
—
LPA (diluído, TTM)
-0.3
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da ABVC Biopharma
Fim do ano fiscalReceitaResultado operacionalLucro líquido
796 mil-7,2 mi-7,9 mi
509,6 mil-4,7 mi-4,9 mi
152,4 mil-6,8 mi-7,8 mi
969,8 mil-15,1 mi-16,4 mi